All In Biotech

Drug Trial Radar · NCT07161843

Use of QRX3 for Acute Tubular Necrosis Type of Renal Failure in Hospitalized Patients ( QRX-3 in ARF)

Determine the Efficacy of Investigational Drug QRX-3 in Hospitalized Patients With Acute Tubular Necrosis Pattern of Acute Renal Failure

Last checked: Nov 19, 2026Latest source record: Feb 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 500 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

500

Planned (sponsor's estimate)

Start

Jun 30, 2026

Primary completion

Dec 30, 2026

Study completion Feb 1, 2027

Sponsor

Lead sponsor
Ebima Clifford OkundayeIndustry
Sponsor type
Industry
First posted
Sep 9, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 10 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Use of QRX-3 in hospitalized patients with pediatric and adult patients with acute tubular necrosis renal failure

Conditions

  • Acute Renal Failure (ARF)
  • Acute Tubular Necrosis

Interventions

  • QRX-3Drug

    Combination of QRX-3 with standard therapy will be given to one arm in trial , another arm will receive placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of change in creatinine glomerular filtration rateTime frame: 28 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Neukidney Inc

    Rosharon, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.